Background: Despite the progress and innovation in chemo-and immunotherapies,
androgen deprivation therapy remains the standard treatment of metastatic prostate cancer …

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer
(CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved …

The androgen signaling axis has been the main therapeutic target in the management of
advanced prostate cancer for several decades. Over the past years, significant advances …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Highlights•Androgen receptor (AR) signaling is a critical driver of prostate cancer cell
proliferation and survival.•Alterations in AR and peripheral production of androgens promote …

Prostate tissue, whether benign or malignant, is heavily dependent on androgen receptor
(AR) signaling for growth and proliferation. Androgen deprivation therapy has been standard …

Prostate cancer is the second-leading cause of cancer-related mortality in men in Western
societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer …

To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …

Since the year 2000, tremendous progress has been made in the understanding of
castration-resistant prostate cancer (CRPC), a disease state now recognized to retain …

After decades of limited success in the treatment of castration-resistant prostate cancer
(CRPC), five novel therapeutics were granted Food and Drug Administration regulatory …